Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313294752> ?p ?o ?g. }
- W4313294752 endingPage "627" @default.
- W4313294752 startingPage "627" @default.
- W4313294752 abstract "Predicting the ability of nanoparticles (NP) to access the tumor is key to the success of chemotherapy using nanotherapeutics. In the present study, the ability of the dual NP-based theranostic system to accumulate in the tumor was evaluated in vivo using intravital microscopy (IVM) and MRI. The system consisted of model therapeutic doxorubicin-loaded poly(lactide-co-glycolide) NP (Dox-PLGA NP) and novel hybrid Ce3/4+-doped maghemite NP encapsulated within the HSA matrix (hMNP) as a supermagnetic MRI contrasting agent. Both NP types had similar sizes of ~100 nm and negative surface potentials. The level of the hMNP and PLGA NP co-distribution in the same regions of interest (ROI, ~2500 µm2) was assessed by IVM in mice bearing the 4T1-mScarlet murine mammary carcinoma at different intervals between the NP injections. In all cases, both NP types penetrated into the same tumoral/peritumoral regions by neutrophil-assisted extravasation through vascular micro- and macroleakages. The maximum tumor contrasting in MRI scans was obtained 5 h after hMNP injection/1 h after PLGA NP injection; the co-distribution level at this time reached 78%. Together with high contrasting properties of the hMNP, these data indicate that the hMNP and PLGA NPs are suitable theranostic companions. Thus, analysis of the co-distribution level appears to be a useful tool for evaluation of the dual nanoparticle theranostics, whereas assessment of the leakage areas helps to reveal the tumors potentially responsive to nanotherapeutics." @default.
- W4313294752 created "2023-01-06" @default.
- W4313294752 creator A5007007872 @default.
- W4313294752 creator A5008015839 @default.
- W4313294752 creator A5010949525 @default.
- W4313294752 creator A5013204418 @default.
- W4313294752 creator A5039224143 @default.
- W4313294752 creator A5044189525 @default.
- W4313294752 creator A5048247977 @default.
- W4313294752 creator A5058039538 @default.
- W4313294752 creator A5058080390 @default.
- W4313294752 creator A5064760094 @default.
- W4313294752 creator A5069389044 @default.
- W4313294752 creator A5076916236 @default.
- W4313294752 creator A5086018071 @default.
- W4313294752 creator A5090046646 @default.
- W4313294752 creator A5090852995 @default.
- W4313294752 date "2022-12-30" @default.
- W4313294752 modified "2023-09-30" @default.
- W4313294752 title "Supermagnetic Human Serum Albumin (HSA) Nanoparticles and PLGA-Based Doxorubicin Nanoformulation: A Duet for Selective Nanotherapy" @default.
- W4313294752 cites W1063491141 @default.
- W4313294752 cites W1867757591 @default.
- W4313294752 cites W1871308790 @default.
- W4313294752 cites W1940048983 @default.
- W4313294752 cites W1976381030 @default.
- W4313294752 cites W1985858988 @default.
- W4313294752 cites W1993334011 @default.
- W4313294752 cites W1999775494 @default.
- W4313294752 cites W2000093612 @default.
- W4313294752 cites W2002936944 @default.
- W4313294752 cites W2025036947 @default.
- W4313294752 cites W2029753193 @default.
- W4313294752 cites W2046527344 @default.
- W4313294752 cites W2047571912 @default.
- W4313294752 cites W2068783587 @default.
- W4313294752 cites W2071778162 @default.
- W4313294752 cites W2076039840 @default.
- W4313294752 cites W2081950007 @default.
- W4313294752 cites W2087414776 @default.
- W4313294752 cites W2089974427 @default.
- W4313294752 cites W2110885272 @default.
- W4313294752 cites W2112719371 @default.
- W4313294752 cites W2126346850 @default.
- W4313294752 cites W2144391591 @default.
- W4313294752 cites W2148932203 @default.
- W4313294752 cites W2149934235 @default.
- W4313294752 cites W2150737519 @default.
- W4313294752 cites W2151020295 @default.
- W4313294752 cites W2173359203 @default.
- W4313294752 cites W2279217276 @default.
- W4313294752 cites W2286353904 @default.
- W4313294752 cites W2337797633 @default.
- W4313294752 cites W2416990306 @default.
- W4313294752 cites W2510384553 @default.
- W4313294752 cites W2530319447 @default.
- W4313294752 cites W2549628327 @default.
- W4313294752 cites W2552976154 @default.
- W4313294752 cites W2554329232 @default.
- W4313294752 cites W2599633442 @default.
- W4313294752 cites W2604947835 @default.
- W4313294752 cites W2606511316 @default.
- W4313294752 cites W2719338461 @default.
- W4313294752 cites W2734416900 @default.
- W4313294752 cites W2755462565 @default.
- W4313294752 cites W2757272801 @default.
- W4313294752 cites W2884443216 @default.
- W4313294752 cites W2884616676 @default.
- W4313294752 cites W2900214628 @default.
- W4313294752 cites W2947560024 @default.
- W4313294752 cites W2949492896 @default.
- W4313294752 cites W2954002791 @default.
- W4313294752 cites W2970329262 @default.
- W4313294752 cites W2973788441 @default.
- W4313294752 cites W2979446109 @default.
- W4313294752 cites W2983762161 @default.
- W4313294752 cites W2990007802 @default.
- W4313294752 cites W2990574737 @default.
- W4313294752 cites W2998882776 @default.
- W4313294752 cites W2999300257 @default.
- W4313294752 cites W3002685488 @default.
- W4313294752 cites W3008910477 @default.
- W4313294752 cites W3014907299 @default.
- W4313294752 cites W3035335179 @default.
- W4313294752 cites W3080342211 @default.
- W4313294752 cites W3113034789 @default.
- W4313294752 cites W3150503279 @default.
- W4313294752 cites W3168240509 @default.
- W4313294752 cites W3184755963 @default.
- W4313294752 cites W3186007287 @default.
- W4313294752 cites W3191894985 @default.
- W4313294752 cites W3203303679 @default.
- W4313294752 cites W3205668747 @default.
- W4313294752 cites W4205494126 @default.
- W4313294752 cites W4221032937 @default.
- W4313294752 cites W4221075212 @default.
- W4313294752 cites W4281638808 @default.
- W4313294752 doi "https://doi.org/10.3390/ijms24010627" @default.
- W4313294752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36614071" @default.